Last quarter (Q4 2023), Humacyte's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Humacyte's net income was $-25.14M. See Humacyte’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21
Total Revenue	-	-	$ 1.56M	$ 1.30M
Cost of Revenue	-	-	-	-
Gross Profit	-	-	$ 1.56M	-
Operating Expense	$ 100.05M	$ 100.05M	$ 86.14M	$ -82.47M
Operating Income	$ -100.01M	$ -100.00M	$ -84.60M	$ -82.52M
Net Non Operating Interest Income Expense	$ -1.13M	$ -1.13M	$ -3.57M	$ -4.33M
Other Income Expense	$ 9.58M	$ 9.58M	$ -77.75M	$ -60.41M
Pretax Income	$ -110.75M	$ -110.75M	$ -11.96M	$ -26.44M
Tax Provision	$ -2.07M	$ -2.07M	$ -1.77M	$ -8.98M
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	$ -110.77M	$ -110.78M	$ -11.96M	$ -26.44M
Basic EPS	$ -1.07	$ -1.07	$ -0.12	$ -0.66
Diluted EPS	$ -1.07	$ -1.07	$ -0.12	$ -0.66
Basic Average Shares	$ 413.68M	$ 103.42M	$ 103.05M	$ 39.97M
Diluted Average Shares	$ 413.68M	$ 103.42M	$ 103.05M	$ 39.97M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	$ 100.05M	$ 100.05M	$ 86.14M	$ -82.47M
Net Income From Continuing And Discontinued Operation	$ -110.78M	$ -110.78M	$ -11.96M	$ -26.44M
Normalized Income	$ -69.80M	$ -102.80M	-	-
Interest Expense	-	-	-	-
EBIT	$ -105.63M	$ -104.16M	$ -5.76M	$ -22.11M
EBITDA	$ -74.68M	$ -95.86M	$ 4.08M	$ -12.83M

Currency in USD

Humacyte Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing